MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-21-2026
Can-Fite BioPharma Ltd. General and Administrative Expenses 2011-2026 | CANF
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Can-Fite BioPharma Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.05 M | 2.96 M | 3.14 M | 3.84 M | 158 K | 132 K | 130 K | 2.96 M | 2.73 M | 2.72 M | 11.6 M | 4.52 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.6 M | 130 K | 3.16 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M |  USA |
 |
Agenus
AGEN
|
78.7 M | $ 3.27 | -1.8 % | $ 1.17 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
180 M | $ 29.33 | -2.98 % | $ 1.7 B | USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
107 M | $ 1.26 | -3.44 % | $ 324 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
9.66 M | $ 0.24 | 1.1 % | $ 5.73 B |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Aldeyra Therapeutics
ALDX
|
9.6 M | $ 5.49 | 0.52 % | $ 330 M | USA |
 |
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alector
ALEC
|
54 M | $ 2.26 | -7.2 % | $ 233 M | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Aligos Therapeutics
ALGS
|
30.6 M | $ 7.02 | -0.21 % | $ 451 M | USA |
 |
Alkermes plc
ALKS
|
222 M | $ 29.32 | -2.61 % | $ 4.83 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
71.7 M | $ 2.57 | -7.73 % | $ 403 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.21 B | $ 330.95 | -0.59 % | $ 43.4 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Altimmune
ALT
|
21 M | $ 4.2 | -2.55 % | $ 298 M | USA |
 |
ALX Oncology Holdings
ALXO
|
26.1 M | $ 2.11 | 0.09 % | $ 110 M | USA |
 |
Amgen
AMGN
|
7.05 B | $ 387.85 | 0.03 % | $ 209 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 20.22 | -0.05 % | $ 945 M | USA |
 |
Amarin Corporation plc
AMRN
|
200 M | $ 13.62 | -1.3 % | $ 5.55 B | Irlanda |
 |
AIM ImmunoTech
AIM
|
13.1 M | $ 0.92 | 5.25 % | $ 44.2 M | USA |
 |
AnaptysBio
ANAB
|
42.4 M | $ 54.61 | -0.8 % | $ 1.55 B | USA |
 |
Anika Therapeutics
ANIK
|
95.8 M | $ 14.44 | 0.53 % | $ 212 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
250 M | $ 75.31 | 1.91 % | $ 1.45 B | USA |
 |
Annexon
ANNX
|
34.6 M | $ 5.38 | -3.93 % | $ 739 M | USA |
 |
Annovis Bio
ANVS
|
6.24 M | $ 2.6 | -2.99 % | $ 23.5 M | USA |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Apellis Pharmaceuticals
APLS
|
550 M | $ 20.53 | -2.05 % | $ 2.59 B | USA |
 |
Aptorum Group Limited
APM
|
5.41 M | $ 0.78 | -0.67 % | $ 4.25 M | China |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Aprea Therapeutics
APRE
|
8.43 M | $ 0.88 | -3.71 % | $ 3.18 M | USA |
 |
Aptevo Therapeutics
APVO
|
10.2 M | $ 7.28 | -0.55 % | $ 2.01 M | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aquestive Therapeutics
AQST
|
50.2 M | $ 3.99 | -0.15 % | $ 346 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
52.8 M | $ 8.11 | -1.44 % | $ 219 M |  Israel |
 |
Ardelyx
ARDX
|
337 M | $ 6.32 | -3.54 % | $ 1.52 B | USA |
 |
Aileron Therapeutics
ALRN
|
13.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
argenx SE
ARGX
|
308 M | $ 762.51 | -0.58 % | $ 25 B |  Niderland |